Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05027815 · ClinicalTrials.gov registry record · Phase 1
Tregs for the Treatment of Acute Respiratory Distress Syndrome (ARDS) Associated With COVID-19 (regARDS)
A Phase 1 study, sponsored by Jeffrey Bluestone.
- Terminated
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT05027815 is a Phase 1 study that was terminated before completion, run by Jeffrey Bluestone. The registered enrollment target is 7 participants.
The verdict
NCT05027815, a Phase 1 study, was terminated before completion, sponsored by Jeffrey Bluestone.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
In patients with Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19 inflammatory syndrome, the administration of Treg cells is a novel treatment complementary to other pharmacologic interventions that potentially can reduce lung inflammation, promote lung tissue repair, and significantly improve clinical outcomes. This trial is to evaluate the impact of a single IV dose of cePolyTregs given to ARDS patients with COVID-19 inflammatory syndrome.
Interventions
- BIOLOGICAL Cryopreserved Ex Vivo Expanded Polyclonal CD4+CD127lo/-CD25+ T Regulatory Cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2021-09-23 |
| Est. Completion | 2022-03-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05027815
The ClinicalTrials.gov registry entry for NCT05027815 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jeffrey Bluestone, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cryopreserved Ex Vivo Expanded Polyclonal CD4+CD127lo/-CD25+ T Regulatory Cells is the first listed.
NCT05027815 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05027815 about?
NCT05027815 is a clinical study titled "Tregs for the Treatment of Acute Respiratory Distress Syndrome (ARDS) Associated With COVID-19 (regARDS)". In patients with Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19 inflammatory syndrome, the administration of Treg cells is a novel treatment complementary to other pharmacologic interventions that potentially can reduce lung inflammation, promote lung tissue repair, and signific...
What is the current status of trial NCT05027815?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2021-09-23. Estimated completion is 2022-03-02.
What interventions are being tested in trial NCT05027815?
The interventions under investigation include: Cryopreserved Ex Vivo Expanded Polyclonal CD4+CD127lo/-CD25+ T Regulatory Cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT05027815?
This trial is sponsored by Jeffrey Bluestone, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.